ZGN-1061 is an experimental drug that was developed by Zafgen for treatment of obesity and type 2 diabetes.

It has a similar mechanism of action as the discontinued drug Beloranib but was considered safer; however, its development was also halted because of safety concerns.

[1][2][3]